Friday, October 30, 2020

QualityStocksNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Featured in BioWorld Article

 VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in a recent BioWorld article titled, “CBC-funded Affamed merges with Everinsight, extends portfolio with Kissei PD candidate.” The publication discusses the merging of Affamed Therapeutics Ltd., an emerging biopharmaceutical company focused on opthamology markets in Greater China and funded by the large global venture capital firm, CBC Group, and EverInsight Therapeutics Inc., a biopharmaceutical company focused on central nervous system disorders and also funded by CBC Group. EverInsight and VistaGen entered into an exclusive development and commercialization agreement for VistaGen’s PH94B neuroactive nasal spray, a Phase 3-entering drug candidate for treatment of social anxiety disorder, earlier this year (https://ibn.fm/W6BOk). Under that agreement, VistaGen received a non-dilutive upfront payment of $5 million and, if Phase 3 development is successful, is eligible for up to $172 million in development and commercial milestone payment, plus royalties on commercial sales. According to the article, Affamed aims to bring in late-stage assets for China and other Asian markets focused on central nervous system and ophthalmology. As a result of the merger, VistaGen will work closely with the combined Affamed/EverInsight team on Phase 3 development and commercialization of PH94B in Greater China, South Korea and Southeast Asia. As noted in the article regarding the Affamed/EverInsight merger: “’In addition to bringing together complementary businesses, the combination strengthens the combined company’s global R&D capabilities,’ Affamed’s CEO Dayao Zhao told BioWorld. After the merger, Affamed now has a neurosteroid nasal spray, PH94B, which is moving into phase III development for social anxiety disorder with licensing rights from Vistagen Therapeutics Inc. in greater China, Korea and Southeast Asia.”

To view the full article, visit https://ibn.fm/ZkMnj

About VistaGen Therapeutics

VistaGen is a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other CNS disorders where the current standard of care is inadequate, resulting in high unmet need. Each of VistaGen’s three drug candidates has a differentiated mechanism of action, an exceptional safety profile in all studies to date, and therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN   

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

No comments: